IT IS USED IN TYPE 2 DIABETES MALLITUS AND ACTS PRIMARILY BY INCREASING INSULIN SENSTIVITY & INHIBITS HEPATIC GLUCONEOGENESIS. IT INDUCES RECOVRY OF BETA CELL FUNCTION, IMPROVES ENDOTHELIAL DYSFUNCTION INDEPENDENT OF GLYCEMIC CONTROL, INCREASES ADIPONECTIN WHICH IS DECREASED IN TYPE - 2 DIABETES, REDUCES RATE OF IN-STENT RESTENOSIS IN TYPE-2 DIABETIC PATIENTS WITH CAD & REDUCES INFLAMMATORY MARKERS LIKE CRP , PAI-1 & E-SELECTIN INDEPENDENT OF GLYCEMIC CONTROL. DURATION OF ACTION IS 12 - 24 HRS